Grifois, S.A.

XNAS

Last traded price · USD

$8.58

−0.35%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $8.61
Volume: 38
Day's high: —
Day's low: —

In brief

Grifois, S.A. is a US-listed company listed on Nasdaq, valued at about $5.84B.
Its shares closed at $8.61 on 4 Nov 2026, down 6.6% over the past year.
From India you can buy GRFS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Grifois, S.A. (GRFS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole GRFS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade GRFS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Above its 50- and 200-day averages
The 4 Nov 2026 close of $8.61 was 12.9% above its 50-day average ($7.62) and 7.7% above its 200-day average ($7.99). It has closed above the 200-day for 7 sessions, since 27 Oct 2026. The 50-day average crossed below the 200-day on 6 Jan 2026, 209 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
15.9 days to cover short interest
7.0M shares were sold short at the 15 Oct 2026 settlement, 2.7% of the 261.4M shares outstanding; covering them would take 15.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY over 1 year
1 month: +14.5% (SPY −1.6%). 3 months: +8.6% (SPY −0.4%). 1 year: −6.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GRFS, SPY · as of 4 Nov 2026
RSI(14) at 76.2, 70 or above
The 14-session relative strength index closed at 76.2 on 4 Nov 2026, its 3rd session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Volume 2.3× its 30-session average on 2 Nov 2026
2 Nov 2026 volume of 1.6M shares was 2.3× the average of the 30 sessions before it (702.9K), as the price rose 5.1%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+14.5%

6 months+2.4%

1 year−6.6%

5 years−31.1%

Newswire

About

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Website

Notable moves

March 8, 2024
+24.78%
February 29, 2024
−19.59%
January 9, 2024
−21.83%

Newswire

About

Website

Notable moves

March 8, 2024
+24.78%
February 29, 2024
−19.59%
January 9, 2024
−21.83%

Grifois, S.A.

XNAS

Last traded price · USD

$8.58

−0.35%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $8.61
Volume: 38
Day's high: —
Day's low: —

In brief

Grifois, S.A. is a US-listed company listed on Nasdaq, valued at about $5.84B.
Its shares closed at $8.61 on 4 Nov 2026, down 6.6% over the past year.
From India you can buy GRFS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Grifois, S.A. (GRFS) shares from India?

Do I need the price of a whole GRFS share to invest?

How much can I invest in US stocks in a year?

Can I trade GRFS options or futures?

Insights

Quotes run fifteen minutes behind.

Above its 50- and 200-day averages
The 4 Nov 2026 close of $8.61 was 12.9% above its 50-day average ($7.62) and 7.7% above its 200-day average ($7.99). It has closed above the 200-day for 7 sessions, since 27 Oct 2026. The 50-day average crossed below the 200-day on 6 Jan 2026, 209 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
15.9 days to cover short interest
7.0M shares were sold short at the 15 Oct 2026 settlement, 2.7% of the 261.4M shares outstanding; covering them would take 15.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY over 1 year
1 month: +14.5% (SPY −1.6%). 3 months: +8.6% (SPY −0.4%). 1 year: −6.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GRFS, SPY · as of 4 Nov 2026
RSI(14) at 76.2, 70 or above
The 14-session relative strength index closed at 76.2 on 4 Nov 2026, its 3rd session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Volume 2.3× its 30-session average on 2 Nov 2026
2 Nov 2026 volume of 1.6M shares was 2.3× the average of the 30 sessions before it (702.9K), as the price rose 5.1%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+14.5%

6 months+2.4%

1 year−6.6%

5 years−31.1%

Newswire

About

Website

Notable moves

March 8, 2024
+24.78%
February 29, 2024
−19.59%
January 9, 2024
−21.83%

Newswire

About

Website

Notable moves

March 8, 2024
+24.78%
February 29, 2024
−19.59%
January 9, 2024
−21.83%

Grifois, S.A.

Grifois, S.A. in brief

Above its 50- and 200-day averages

15.9 days to cover short interest

Behind SPY over 1 year

RSI(14) at 76.2, 70 or above

Volume 2.3× its 30-session average on 2 Nov 2026

Grifois, S.A.

Grifois, S.A. in brief

Above its 50- and 200-day averages

15.9 days to cover short interest

Behind SPY over 1 year

RSI(14) at 76.2, 70 or above

Volume 2.3× its 30-session average on 2 Nov 2026